Pooled Analysis Supports Use of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

December 7, 2020
Jennifer R. Brown, MD, PhD

Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, director, Chronic Lymphocytic Lueukemia (CLL) Center, Dana-Farber Cancer Institute, and professor, Medicine, Harvard Medical School, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation Bruton’s kinase (BTK) inhibitor acalabrutinib (Calquence) monotherapy as treatment of patients with CLL.

The findings, which were presented during the 2020 American Society of Hematology (ASH) Annual Meeting, support what has been seen in the clinic, says Brown. The cardiovascular adverse events were reduced with acalabrutinib compared with ibrutinib (Imbruvica).

In Brown’s practice, she tends to favor acalabrutinib over ibrutinib for most patients. The next-generation BTK inhibitor should strongly be considered for patients with known cardiac risk factors, according to Brown, but head-to-head comparison data for 17p and 11q in patients with CLL are expected sometime in the next year.